Q-omics provides the consensus-scored ZNF414 profile across patient tissues and cancer cell-line models. ZNF414 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF414 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, ZNF414 RNA expression shows 19,062 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where ZNF414 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF414 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF414 survival associations across molecular data types. ZNF414 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF414 RNA expression–survival associations across cancer types. High ZNF414 expression shows unfavorable associations in ACC and UCS, but favorable associations in HNSC, BLCA, UCEC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF414 RNA expression.
This table summarizes ZNF414 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF414. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF414 shows lower tumor expression in THCA and LUAD and higher tumor expression in LIHC, COAD, KIRC and KIRP. The LIHC box plot shows higher ZNF414 RNA expression in tumor versus normal tissue (log2 FC = +1.200, t-test p < 0.001).
This table shows molecular features associated with ZNF414 in patient tissues and cancer cell lines. In patient samples, ZNF414 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF414 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
